Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Provision for (benefit from) income taxes by Quarter
Provision for (benefit from) income taxes — Total ($M) ($M)
Vertex Pharmaceuticals Provision for (benefit from) income taxes: $292M in Q2 2026, up 16.8% from a year earlier. That is the highest of the 62 quarters on record here.
Latest, Q2 2026
292
Period ended Jun 30, 2026
Change on a year earlier
+16.8%
250 in Q2 2025
History
62 quarters
Since Q1 2011
Sources
36
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Income Taxes).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Provision for (benefit from) income taxes — Total ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 292 | +16.8% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 222 | +163.4% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 140 | -37.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 216 | +20.8% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 250 | +23.6% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 84.1 | -53.1% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 224 | +25.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 179 | +24.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 202 | -17.7% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 180 | -6.4% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2023 | Dec 31, 2023 | 179 | -30.7% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 144 | -41.5% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2023 | Jun 30, 2023 | 246 | +14.9% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 192 | -0.5% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2022 | Dec 31, 2022 | 258 | +155.9% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | 246 | +6.5% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 214 | -292.4% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 193 | +14.8% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2021 | Dec 31, 2021 | 101 | -64.6% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | 231 | +194.5% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | -111 | +789.6% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 168 | +206.2% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 284 | +203.5% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2020 | Sep 30, 2020 | 78.4 | +493.9% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | -12.5 | -120.9% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2020 | Mar 31, 2020 | 54.8 | +6.4% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 93.7 | -106.3% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2019 | Sep 30, 2019 | 13.2 | +63.0% | Form 10-K (filed 2021-02-11) ↗ |
| Q2 2019 | Jun 30, 2019 | 59.7 | +479.6% | Form 10-K (filed 2021-02-11) ↗ |
| Q1 2019 | Mar 31, 2019 | 51.5 | -505.5% | Form 10-K (filed 2021-02-11) ↗ |
| Q4 2018 | Dec 31, 2018 | -1,493 | -14,591.3% | Form 10-K (filed 2020-02-13) ↗ |
| Q3 2018 | Sep 30, 2018 | 8.10 | -106.4% | Form 10-K (filed 2020-02-13) ↗ |
| Q2 2018 | Jun 30, 2018 | 10.3 | +139.5% | Form 10-K (filed 2020-02-13) ↗ |
| Q1 2018 | Mar 31, 2018 | -12.7 | -417.5% | Form 10-K (filed 2020-02-13) ↗ |
| Q4 2017 | Dec 31, 2017 | 10.3 | -237.3% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | -126 | -25,280.0% | Form 10-K (filed 2019-02-13) ↗ |
| Q2 2017 | Jun 30, 2017 | 4.30 | -76.2% | Form 10-K (filed 2019-02-13) ↗ |
| Q1 2017 | Mar 31, 2017 | 4 | -27.3% | Form 10-K (filed 2019-02-13) ↗ |
| Q4 2016 | Dec 31, 2016 | -7.50 | +435.7% | Form 10-K (filed 2018-02-15) ↗ |
| Q3 2016 | Sep 30, 2016 | 0.50 | -61.5% | Form 10-K (filed 2018-02-15) ↗ |
| Q2 2016 | Jun 30, 2016 | 18.1 | -39.9% | Form 10-K (filed 2018-02-15) ↗ |
| Q1 2016 | Mar 31, 2016 | 5.50 | +1,733.3% | Form 10-K (filed 2018-02-15) ↗ |
| Q4 2015 | Dec 31, 2015 | -1.40 | -170.0% | Form 10-K (filed 2017-02-23) ↗ |
| Q3 2015 | Sep 30, 2015 | 1.30 | -61.8% | Form 10-K (filed 2017-02-23) ↗ |
| Q2 2015 | Jun 30, 2015 | 30.1 | +4,200.0% | Form 10-K (filed 2017-02-23) ↗ |
| Q1 2015 | Mar 31, 2015 | 0.30 | -62.5% | Form 10-K (filed 2017-02-23) ↗ |
| Q4 2014 | Dec 31, 2014 | 2 | +42.9% | Form 10-K (filed 2015-02-13) ↗ |
| Q3 2014 | Sep 30, 2014 | 3.40 | +30.8% | Form 10-Q (filed 2014-11-06) ↗ |
| Q2 2014 | Jun 30, 2014 | 0.70 | +16.7% | Form 10-Q (filed 2014-07-31) ↗ |
| Q1 2014 | Mar 31, 2014 | 0.80 | -100.6% | Form 10-Q (filed 2014-05-05) ↗ |
| Q4 2013 | Dec 31, 2013 | 1.40 | -151.9% | Form 10-K (filed 2015-02-13) ↗ |
| Q3 2013 | Sep 30, 2013 | 2.60 | -87.9% | Form 10-Q (filed 2014-11-06) ↗ |
| Q2 2013 | Jun 30, 2013 | 0.60 | -97.0% | Form 10-K (filed 2015-02-13) ↗ |
| Q1 2013 | Mar 31, 2013 | -127 | – | Form 10-K (filed 2015-02-13) ↗ |
| Q4 2012 | Dec 31, 2012 | -2.70 | -111.9% | Form 10-K (filed 2013-03-01) ↗ |
| Q3 2012 | Sep 30, 2012 | 21.4 | -177.0% | Form 10-Q (filed 2012-11-06) ↗ |
| Q2 2012 | Jun 30, 2012 | 20.1 | -17.6% | Form 10-Q (filed 2012-08-08) ↗ |
| Q1 2012 | Mar 31, 2012 | 0 | – | Form 10-Q (filed 2012-05-10) ↗ |
| Q4 2011 | Dec 31, 2011 | 22.7 | – | Form 10-K (filed 2012-02-22) ↗ |
| Q3 2011 | Sep 30, 2011 | -27.8 | – | Form 10-Q (filed 2011-11-03) ↗ |
| Q2 2011 | Jun 30, 2011 | 24.4 | – | Form 10-Q (filed 2011-08-09) ↗ |
| Q1 2011 | Mar 31, 2011 | 0 | – | Form 10-K (filed 2013-03-01) ↗ |
Breakdown
What makes up provision for (benefit from) income taxes
Cite this data
StockData. (2026). Vertex Pharmaceuticals Provision for (benefit from) income taxes ($M), quarterly Q1 2011–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/tax-exp-tot
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.